Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations
Mené sur 107 patients atteints d'un mélanome de stade avancé, cet essai évalue l'efficacité, du point de vue de la survie globale, et la toxicité à long terme du nivolumab, un anticorps monoclonal anti PD-1
Decades of research suggesting an association between tumors and immune tolerance have led to the development of an array of immunotherapeutic strategies to reactivate the adoptive and innate immune system against tumor antigens. Understanding of this association has led to the development of multiple immunotherapy approaches, including immune checkpoint inhibition. Emerging clinical data, such as those presented in the article by Topalian et al that accompanies this editorial, introduce the possibility that not only can these immunotherapy treatments be added to treatment regimens, but perhaps they can raise survival curves to new heights...